I am not talking about letting go of complete control
Key Research Areas for FOXO4-DRI FOXO4p53 protein-protein interaction disruption assays co-immunoprecipitation (CO-IP) and competitive binding studies Senescent cell identification and selective elimination assays SA--galactosidase, p16, p21, p53 staining combined with FOXO4-DRI apoptosis induction p53 TAD2 binding, nuclear exclusion, and mitochondrial translocation studies phospho-p53 (Ser15) pathway research BAX/BCL-2/Caspase-3 intrinsic apoptosis pathway investigations in senescent cell models SASP (Senescence-Associated Secretory Phenotype) characterisation and suppression IL-6, IL-8, MMP, VEGF, CXCL2/3 pathway studies Tissue-specific senescent cell biology fibroblasts, endothelial cells, Leydig cells, chondrocytes, epithelial cells Vascular ageing pathway research endothelial cell senescence, aortic function, and ROS/oxidative stress studies Senescent Leydig cell and male reproductive ageing models FOXO4 nuclear translocation and testosterone synthesis pathway research Chondrocyte senescence and cartilage biology senescent cell removal and chondrogenic potential restoration studies Keloid and pathological scar biology senescent fibroblast elimination and SASP suppression in fibrotic tissue models Senescent cancer cell elimination FOXO4-DRI as a senolytic tool in oncology research models Comparative senolytic research FOXO4-DRI vs
17-OH progesterone: Helps determine adrenal reserve
such as tendons, ligaments, brain, bone, etc Effective treatment for Traumatic brain injury (TBI) Protects and heals Inflamed Intestinal Epithelium (Leaky Gut Syndrome) Conditions BPC 157 has Improved or Helped with: Lymes disease Chronic viral or intracellular infections Chronic Fatigue Syndrome /Fibromyalgia Autoimmune Disease Inflammatory conditions Cardiovascular Disease Post-surgical repair Muscle Strains Ligament Sprains References: Some of the information shared in this post was referenced from our manufacturer Tavo Health
